Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial - Merit Cudkowicz, Angela Genge, Nicholas Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V. Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al-Chalabi, Matthew Kiernan, Susan Mathers, Robert Henderson, Merrilee Needham, David Schultz - Dissemin

Language
Login

Published in

Elsevier, The Lancet Neurology, 10(20), p. 821-831, 2021

DOI: 10.1016/s1474-4422(21)00242-8

Links

Tools

Export citation

Search in Google Scholar

Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Journal article published in 2021 by Merit Cudkowicz, Angela Genge, Nicholas Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V. Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al-Chalabi, Matthew Kiernan, Susan Mathers, Robert Henderson, Merrilee Needham, David Schultz and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO